Bank of New York Mellon Corp Has $12.55 Million Stock Holdings in argenex SE $ARGX

Bank of New York Mellon Corp raised its position in argenex SE (NASDAQ:ARGX) by 3.8% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 17,183 shares of the company’s stock after buying an additional 634 shares during the period. Bank of New York Mellon Corp’s holdings in argenex were worth $12,548,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Oppenheimer & Co. Inc. lifted its position in argenex by 2.8% during the 4th quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company’s stock valued at $372,000 after purchasing an additional 12 shares during the period. Valeo Financial Advisors LLC grew its holdings in argenex by 0.9% during the 4th quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock worth $1,153,000 after acquiring an additional 12 shares during the period. CI Investments Inc. raised its position in shares of argenex by 2.6% during the 4th quarter. CI Investments Inc. now owns 469 shares of the company’s stock valued at $394,000 after acquiring an additional 12 shares during the last quarter. Allworth Financial LP raised its position in shares of argenex by 12.7% during the 4th quarter. Allworth Financial LP now owns 115 shares of the company’s stock valued at $97,000 after acquiring an additional 13 shares during the last quarter. Finally, WPG Advisers LLC lifted its stake in shares of argenex by 17.8% in the 1st quarter. WPG Advisers LLC now owns 86 shares of the company’s stock valued at $63,000 after purchasing an additional 13 shares during the period. Institutional investors own 60.32% of the company’s stock.

argenex Price Performance

NASDAQ ARGX opened at $853.82 on Friday. The firm has a market cap of $53.41 billion, a P/E ratio of 32.79, a P/E/G ratio of 1.14 and a beta of 0.45. The stock’s 50-day moving average is $875.66 and its 200-day moving average is $817.63. argenex SE has a one year low of $631.47 and a one year high of $953.58.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.86 by $1.46. argenex had a return on equity of 43.59% and a net margin of 32.19%.The business had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.45 billion. Equities analysts anticipate that argenex SE will post 27.11 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Oppenheimer lifted their price objective on argenex from $1,014.00 to $1,037.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Bank of America raised their target price on argenex from $1,016.00 to $1,088.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd. Morgan Stanley upped their price target on argenex from $1,170.00 to $1,180.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. Robert W. Baird increased their price target on shares of argenex from $867.00 to $932.00 and gave the company a “neutral” rating in a research report on Monday, July 27th. Finally, Citizens Jmp reduced their price objective on shares of argenex from $944.00 to $932.00 and set a “market outperform” rating on the stock in a research note on Friday, July 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, argenex presently has an average rating of “Moderate Buy” and an average target price of $1,056.89.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.